Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- For U.S. patents that may apply, see bd.com/patents.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
- Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- An isotype control should be used at the same concentration as the antibody of interest.
- CF™ is a trademark of Biotium, Inc.
- Tandem fluorochromes contain both an energy donor and an energy acceptor. Although every effort is made to minimize the lot-to-lot variation in the efficiency of the fluorochrome energy transfer, differences in the residual emission from the donor may be observed. Additionally, multi-laser cytometers may directly excite both the donor and acceptor fluorochromes. Therefore, we recommend for every tandem conjugate, a matched individual single-stain control be acquired for generating a compensation or spectral unmixing matrix.
Companion Products
The HM7-10 monoclonal antibody specifically binds to the FAIM3-encoded high affinity receptor for IgM (also known as, Fcµ Receptor, FcµR, Fc mu receptor, Immunoglobulin mu Fc receptor, FcmR, IgM Fc receptor). The FcµR is a type 1 transmembrane glycoprotein that contains an extracellular Ig-like domain with sequence similarities to Fcα/µR and pIgR. It is likewise known as Fas apoptotic inhibitory molecule 3, TOSO or Regulator of Fas-induced apoptosis Toso based on its capacity to counter apoptosis mediated by Fas/CD95 (or TNF) in some experimental model systems. FcµRs are expressed by B cells, CD4+ T cells, CD8+ T cells, and NK cells and are highly expressed on Chronic Lymphocytic Leukemia cells. FcµRs may play roles in cellular activation, antigen presentation and IgM-dependent cell-mediated cytotoxicity. The relatively long cytoplasmic tail of FcµR contains several conserved tyrosine and serine residues. These get phosphorylated after FcµR ligation with IgM immune complexes and may initiate signaling responses. Lymphocyte FcµRs can mediate the internalization of IgM-bound antigens including microbial and viral antigens. This in turn may cause cellular activation due to subsequent antigen processing and exposure of activating ligands to intracellular receptors including Toll-like receptors. The HM7-10 antibody reportedly recognizes an epitope near the IgM ligand binding site of the FcµR whereas, a related FcµR-specific antibody, HM14-1 antibody does not. The HM7 epitope is sensitive to IgM ligand binding.
Development References (5)
-
Hitoshi Y, Lorens J, Kitada SI, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity. 1998; 8(4):461-471. (Biology). View Reference
-
Kubagawa H, Oka S, Kubagawa Y, et al. Identity of the elusive IgM Fc receptor (FcmuR) in humans.. J Exp Med. 2009; 206(12):2779-2793. (Immunogen: Flow cytometry, Immunoprecipitation, Western blot). View Reference
-
Shima H, Takatsu H, Fukuda S, et al. Identification of TOSO/FAIM3 as an Fc receptor for IgM.. Int Immunol. 2010; 22(3):149-156. (Biology). View Reference
-
Vire B, David A, Wiestner A. TOSO, the Fcμ receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation. J Immunol. 2011; 187(8):4040-4050. (Biology). View Reference
-
Wines BD, Trist HM, Farrugia W, et al. A conserved host and pathogen recognition site on immunoglobulins: structural and functional aspects. Adv Exp Med Biol. 2012; 946:87-112. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.